You are here: Industry Insights > AML

News List

NICE recommend venetoclax and azacytidine for patients with aggressive blood cancer PharmaTimes
December 17, 2021
Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia prnasia
November 05, 2021
The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML).
Anti-Money Laundering (AML) Software Market to grow over $ 2 Bn during 2021-2025 | COVID-19 Impact & Analysis | 17,000+ Technavio Research Reports prnewswire
September 22, 2021
Anti-Money Laundering (AML) Software Market highlights COVID-19 Recovery for Application Software Industry.
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas firstwordpharma
August 20, 2021
Marker today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the CPRIT to support the Company's Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401.
Pandemic spurs banks' AI adoption for AML, SAS study shows prnewswire
August 11, 2021
A third of financial institutions are accelerating their AI and machine learning (ML) adoption for anti-money laundering (AML) technology in response to COVID-19.
Magenta slips after FDA hold on early-stage trial of MGTA-117 in AML, MDS firstwordpharma
July 22, 2021
Magenta Therapeutics said Wednesday that it has received an FDA clinical hold letter regarding the investigational new drug application it filed in June to start a Phase I/II trial of MGTA-117 in patients with acute myeloid leukaemia (AML) and myelodyspla
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia prnasia
July 13, 2021
Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia.
Bristol Myers Squibb Receives European Commission Approval for Onureg® as Oral Therapy for Adults with Leukemia americanpharmaceuticalreview
June 23, 2021
Bristol Myers Squibb announced that the European Commission (EC) has granted full Marketing Authorization for Onureg® (azacitidine tablets) as maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) ...
MHRA approves Venclyxto for newly diagnosed AML pharmatimes
June 16, 2021
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML).
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia worldpharmanews
May 26, 2021
Roche announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page